Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients with Castration-Resistant Prostate Cancer

Trial Status: closed to accrual

This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with castration-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that may block another signal that can cause prostate cancer cell growth. Prednisone is a drug that can help lessen inflammation. Giving abiraterone acetate, niclosamide, and prednisone may be a better treatment for patients with castration-resistant prostate cancer.